Ariad Pharmaceuticals Inc fka ARIA

[glass_half_full]

[ALK] is a space (like CML) where preclinical results are highly predictive of clinical results....

This is an interesting statement/contention -- with ALK so new a target, why are we confident?

Everything else I think makes sense, but the idea that there is a whole class of compounds whose path through the clinic is well predicted by in vitro or mouse models seems, well, rather optimistic.

I would be very interested to know more about why we think this.